Recent Developments in the Treatment of Advanced and Metastatic RCC

Slides:

Advertisements

Similar presentations

¿Qué ver en ASCO 2017?.

Advertisements

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Case Discussion A 52-year-old man initially presented with nonmuscle-invasive bladder cancer He received Bacillus calmette-guerin (BCG) therapy After.

Evolving Paradigms in Recurrent/Metastatic SCCHN

Diabetic Dyslipidemia in Practice

Nat. Rev. Clin. Oncol. doi: /nrclinonc

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Treatment Algorithms in Melanoma: Past, Present, and Future

Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

Program Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers.

Advanced NSCLC Without Actionable Mutations

State of the Art in HCC: Immune Checkpoint Modulation

New Patient Journeys in Non-small cell lung cancer

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Progression After Cancer Immunotherapy in Advanced NSCLC

Spotlight on Immuno-Oncology in Melanoma

Metastatic Renal Cell Carcinoma

Updates in Lung Cancer: Insights From Vienna

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Optimizing Outcomes in the Management of GIST

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Activity Goals. Activity Goals Discussion Topics.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Management of Glioblastoma

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Checkpoint Inhibition

Basics of Immunotherapy Potential Therapeutic Targets.

Treating mRCC After Initial Antiangiogenic Therapy:

Advanced Lung Cancers: What's on the Horizon?

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Gene Therapy: Past, Present, and Future

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advances in Gastrointestinal Cancers

Figure 2 Site of action of checkpoint inhibitors and agonists being

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Management of Advanced Pancreatic Adenocarcinoma

Challenges in LA SCCHN.

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

Checkpoint Inhibitors in First-Line Advanced NSCLC

Activity Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Genitourinary Cancers.

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

Going Beyond EXTREME in Head and Neck Cancer

Redefiniendo el Tratamiento del Cáncer Renal

Moving Care Forward in Advanced Gastric Cancer

New Options for the Treatment of Hepatocellular Carcinoma

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Immune Checkpoint Inhibitors in Lung Cancer

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View.

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Presentation transcript:

Recent Developments in the Treatment of Advanced and Metastatic RCC

Introduction

CheckMate-214: Nivolumab + Ipilimumab

CheckMate-214: Results for Patients With Intermediate/Poor-Risk Disease[a,b]

CheckMate-214: Results for Patients With Favorable-Risk Disease

How Do You Treat?

Nivolumab/Ipilimumab in Patients With Disease With Sarcomatoid Features

Approval of Nivolumab/Ipilimumab in Europe

Checkpoint Inhibition + VEGF Inhibition

KEYNOTE-426: Pembrolizumab + Axitinib

KEYNOTE-426: Results

Pembrolizumab + Axitinib in Patients With Disease With Sarcomatoid Features

JAVELIN Renal 101: Avelumab + Axitinib

JAVELIN Renal 101: Results

IMmotion 151: Atezolizumab + Bevacizumab

Ongoing Phase 3 Trials in the First Line for Patients With Advanced RCC

Implications of These Results for Patients With Favorable-Risk Disease

Implications of These Results for Patients With Intermediate/Poor-Risk Disease

Complete Response Rate

Debulking Nephrectomy

Debulking Nephrectomy (cont)

Biomarkers

Second-Line Therapy

Concluding Remarks

Abbreviations

Abbreviations (cont)